P
PSYB
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, PSYB has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +29% growth.
Stocks Performance
PSYB vs S&P TSX Composite Index (Canada)
Performance Gap
PSYB vs S&P TSX Composite Index (Canada)
Performance By Year
PSYB vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Psybio Therapeutics Corp
Glance View
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
